Neeta B. Amin

1.4k citations

24 papers · 915 indexed · h-index 15

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes Treatment and Management 7
- Diet, Metabolism, and Disease 5
Hematology top 5%
Nephrology top 5%
- Dialysis and Renal Disease Management 3
Genetics top 10%
Biochemistry top 10%
- Lipid metabolism and biosynthesis 3
Epidemiology
- Liver Disease Diagnosis and Treatment 7
Molecular Biology
- Metabolism, Diabetes, and Cancer 7
Surgery
- Pancreatic function and diabetes 6
Physiology
- Diet and metabolism studies 3

Co-authors: Gianluca Nucci J. V. Anandan Anatole Besarab Susan Vogel Ajay Gupta Stanley Frinak Muhammad Ahsan James M. Rusnak
Cited by: Endocrinology, Diabetes and Metabolism Hematology Nephrology
Journals: Scientific Reports (1 paper)Kidney International (1 paper)CHEST Journal (2 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Neeta B. Amin

23 papers receiving 887 citations

Peers

Countries citing papers authored by Neeta B. Amin

Since Specialization

Citations

This map shows the geographic impact of Neeta B. Amin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neeta B. Amin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neeta B. Amin more than expected).

Fields of papers citing papers by Neeta B. Amin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neeta B. Amin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neeta B. Amin. The network helps show where Neeta B. Amin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Neeta B. Amin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Neeta B. Amin Line = papers co-authored together Neeta B. Amin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study The Lancet. Gastroenterology & hepatology ·Vincent Wai‐Sun Wong,Neeta B. Amin,Hirokazu Takahashi,Amanda Darekar,Frank Tacke,Jan Kiszko,Hector Rodriguez,Atsushi Nakajima,Naim Alkhouri,Michael Charlton,Quentin M. Anstee	2025	5
2	Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study Diabetes Obesity and Metabolism ·Neeta B. Amin,Robert Frederich,Nikolaos Tsamandouras,Amina Z. Haggag,Tilman Schuster,Witold Żmuda,Alexandra Palmer,Szilárd Vasas,Gina Buckley,Timothy R. Smith,Sarah Dubrava,Qi Zhu,Margot Johnson	2024	13
3	Exposure–response modeling of liver fat imaging endpoints in non‐alcoholic fatty liver disease populations administered ervogastat alone and co‐administered with clesacostat CPT Pharmacometrics & Systems Pharmacology ·Jim H. Hughes,Neeta B. Amin,Jessica Wojciechowski,Manoli Vourvahis	2024	0
4	SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH) Scientific Reports ·Pitchumani Sivakumar,Michelle Saul,Douglas S. Robinson,Lindsay E. King,Neeta B. Amin	2024	7
5	Qualified kidney injury biomarkers demonstrate value during early clinical drug development Toxicological Sciences ·Kodihalli C. Ravindra,Kelly A. Fader,David M. Potter,Zaher A. Radi,Gary S. Friedman,Karrie A. Brenneman,Neeta B. Amin,Roberta C. Weiss,Spencer I. Danto,Karen Page,Shashi K. Ramaiah,Vishal S. Vaidya	2024	3
6	Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology Clinical Therapeutics ·Neeta B. Amin,Aditi R. Saxena,Veena Somayaji,Robert Dullea	2023	25
7	Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans Xenobiotica ·Tim F. Ryder,Arthur Bergman,Amanda King‐Ahmad,Neeta B. Amin,Manjinder S. Lall,T. Eric Ballard,Amit S. Kalgutkar	2022	3
8	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study BMJ Open ·Neeta B. Amin,Amanda Darekar,Quentin M. Anstee,Vincent Wai‐Sun Wong,Frank Tacke,Manoli Vourvahis,Douglas S. Lee,Michael Charlton,Naim Alkhouri,Atsushi Nakajima,Carla Yunis	2022	40
9	Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Clinical Pharmacokinetics ·Daryl J. Fediuk,Gianluca Nucci,Vikas Kumar Dawra,David L. Cutler,Neeta B. Amin,Steven G. Terra,Rebecca A. Boyd,Rajesh Krishna,Vaishali Sahasrabudhe	2020	44
10	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study Clinical Pharmacology in Drug Development ·Arthur Bergman,Santos Carvajal‐Gonzalez,Sanela Tarabar,Aditi R. Saxena,William P. Esler,Neeta B. Amin	2020	50
11	Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis Science Translational Medicine ·Neeta B. Amin,Santos Carvajal‐Gonzalez,Julie J. Purkal,Tong Zhu,Collin Crowley,Sylvie Perez,Kristin Chidsey,Albert M. Kim,Bryan Goodwin	2019	48
12	Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active‐Controlled Study Clinical Pharmacology in Drug Development ·William S. Denney,Douglas Denham,Michael R. Riggs,Neeta B. Amin	2016	18
13	Two dose‐ranging studies with PF ‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes Diabetes Obesity and Metabolism ·Neeta B. Amin,Naresh Aggarwal,Dénes Páll,György Paragh,William S. Denney,Lê Văn Duyệt,Michael R. Riggs,Roberto A. Calle	2015	36
14	Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin Diabetes Obesity and Metabolism ·Neeta B. Amin,X. Wang,Sunil Jain,D. S. Lee,Gianluca Nucci,James M. Rusnak	2015	57
15	Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator Drug Metabolism and Disposition ·Raman Sharma,John Litchfield,Karen Atkinson,Heather Eng,Neeta B. Amin,William S. Denney,John C. Pettersen,Theunis C. Goosen,Li Di,Esther Lee,Jeffrey A. Pfefferkorn,Deepak Dalvie,Amit S. Kalgutkar	2014	15
16	Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects Drug Metabolism and Disposition ·Zhuang Miao,Gianluca Nucci,Neeta B. Amin,Raman Sharma,Vincent Mascitti,Meera Tugnait,Alfin D. N. Vaz,Ernesto Callegari,Amit S. Kalgutkar	2012	102
17	Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients Journal of the American Society of Nephrology ·Anatole Besarab,Neeta B. Amin,Muhammad Ahsan,Susan Vogel,GARY ZAZUWA,Stanley Frinak,James Zazra,J. V. Anandan,Ajay Gupta	2000	210
18	Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis Kidney International ·Ajay Gupta,Neeta B. Amin,Anatole Besarab,Susan Vogel,George Divine,Jerry Yee,J. V. Anandan	1999	45
19	Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes American Journal of Kidney Diseases ·Neeta B. Amin,I. Desmond Padhi,Mark A. Touchette,Rakesh Patel,Thomas P. Dunfee,J. V. Anandan	1999	29
20	Atrial Fibrillation After Bypass Surgery CHEST Journal ·Steven Borzak,James E. Tisdale,Neeta B. Amin,A.David Goldberg,Diane M. Frank,I. Desmond Padhi,Robert S.D. Higgins	1998	97

About Neeta B. Amin

Neeta B. Amin is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Biochemistry, having authored 24 papers that have together received 915 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (7 papers), Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (7 papers), Pancreatic function and diabetes (6 papers), Diet, Metabolism, and Disease (5 papers), Lipid metabolism and biosynthesis (3 papers), Diet and metabolism studies (3 papers) and Dialysis and Renal Disease Management (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (374 citations), Hematology (236 citations) and Nephrology (136 citations). Neeta B. Amin has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Gianluca Nucci, J. V. Anandan, Anatole Besarab, Susan Vogel, Ajay Gupta, Stanley Frinak, Muhammad Ahsan, James M. Rusnak, X. Wang and I. Desmond Padhi. Their work appears in journals such as Scientific Reports, Kidney International and CHEST Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact